Literature DB >> 8004328

Rapidly progressive bronchiolitis obliterans with organizing pneumonia.

A J Cohen1, T E King, G P Downey.   

Abstract

Bronchiolitis obliterans with organizing pneumonia (BOOP) is a distinct clinical pathologic syndrome. Most patients experience a good response to therapy, and death from progressive BOOP is uncommon. This report describes the clinical features, etiologic factors, pathologic findings, and outcome of 10 patients with rapidly progressive BOOP that was characterized by severe respiratory failure. The major clinical manifestations were dyspnea, cough, fever, crackles on chest examination, and hypoxemia at rest. Underlying conditions or exposures included connective-tissue disease, exposure to birds, and chronic nitrofurantoin therapy. All patients had the characteristic histopathologic findings of BOOP. However, at autopsy in six patients, the predominant histologic pattern was that of alveolar septal inflammation and fibrotic honeycombing. Seven patients died and three patients survived but had persistent pulmonary dysfunction despite aggressive care. In two patients BOOP has progressed, with severe chronic respiratory decompensation. Thus, there is a subset of patients with BOOP who present with a fulminant course leading to death or chronic severe fibrosis and marked impairment of lung function. In addition, the histologic picture of BOOP may be a manifestation of early lung injury that can resolve or progress rapidly to alveolar septal inflammation, end-stage fibrosis, and honeycombing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8004328     DOI: 10.1164/ajrccm.149.6.8004328

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  24 in total

Review 1.  Organising pneumonia.

Authors:  J F Cordier
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

2.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-2002. A 56-year-old man with rapidly worsening dyspnea.

Authors:  Michelle Ng Gong; Eugene J Mark
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

3.  Nitrofurantoin-induced pulmonary reaction involving respiratory symptoms: case report.

Authors:  Zahra Kanji; Victoria C H Su; Raj Mainra
Journal:  Can J Hosp Pharm       Date:  2011-09

Review 4.  Organizing pneumonia: a kaleidoscope of concepts and morphologies.

Authors:  Benjamin J Roberton; David M Hansell
Journal:  Eur Radiol       Date:  2011-07-10       Impact factor: 5.315

Review 5.  Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Authors:  Carmen Maria Lara Rojas; Elisabetta Borella; Lavinia Palma; Silvio Ragozzino; Enrique De Ramón; Ricardo Gomez-Huelgas; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

6.  Intravenous immune globulins (IVIg) treatment for organizing pneumonia in a selective IgG immune deficiency state.

Authors:  Itai Gueta; Yehuda Shoenfeld; Hedi Orbach
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

7.  Organizing pneumonia revisited: insights and uncertainties from a series of 67 patients.

Authors:  A L Vieira; A Vale; N Melo; P Caetano Mota; J M Jesus; R Cunha; S Guimarães; C Souto Moura; A Morais
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 8.  Bronchiolitis obliterans with organising pneumonia: outcome.

Authors:  U Costabel; J Guzman; H Teschler
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

9.  Nitrofurantoin-associated bronchiolitis obliterans organizing pneumonia: report of a case.

Authors:  Mark E Fenton; Rani Kanthan; Donald W Cockcroft
Journal:  Can Respir J       Date:  2008-09       Impact factor: 2.409

10.  Bronchiolitis obliterans organizing pneumonia: pathogenesis, clinical features, imaging and therapy review.

Authors:  Sara Al-Ghanem; Hamdan Al-Jahdali; Hanaa Bamefleh; Ali Nawaz Khan
Journal:  Ann Thorac Med       Date:  2008-04       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.